Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks.

Abstract

The effectiveness of treating human brucellosis caused by Brucella melitensis with a 6-week course of doxcycline plus streptomycin for 2 of those weeks was analyzed by a multicenter prospective study of 139 patients. Subjects with central nervous system involvement, endocarditis, or spondylitis were excluded from the study. All but 5 of the 139 patients completed the full treatment schedule and became afebrile in the first week of therapy. Four patients suffered relapses during the follow-up period. Of the five patients who did not complete the treatment, two left because of adverse secondary effects (1.4%), another two left for noncomplicance with the treatment (1.4%), and the remaining patient was considered a therapeutic failure because his symptoms persisted after the first week of therapy (0.7%). We concluded that the combination of doxycycline and streptomycin is an effective treatment for the types of brucellosis included in our study.

• Authors: J M Cisneros, P Viciana, J Colmenero, J Pachón, C Martinez, A Alarcón
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 34 Issue 5 Pg. 881-3 (May 1990) ISSN: 0066-4804 [Print] United States
• PMID: 2193624 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Doxycycline
• Streptomycin

Topics

• Adolescent
• Adult
• Aged
• Brucellosis (drug therapy, microbiology)
• Child
• Doxycycline (administration & dosage, adverse effects, therapeutic use)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Multicenter Studies as Topic
• Prospective Studies
• Recurrence
• Streptomycin (administration & dosage, adverse effects, therapeutic use)